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Abstract 
Modelling the solubility of compounds in the “beyond Rule of 5” (bRo5) chemical space is in its infancy and 
to date only a few studies have been reported in the literature. Based on our own results, and those 
already published, we conclude that consideration of conformational flexibility and chameleon like 
behaviour is important, but quantitative models that account for these properties remain to be developed. 
Inclusion of 3D information appears to be somewhat less important than for cell permeability and 
extremely challenging due to the difficulties of accurate conformational sampling in the bRo5 space. 
Currently, methods for modelling of solubility will have to be tailored to the set of investigated 
compounds. 
©2020 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Solubility, and solubility in the bRo5 chemical space 
Aqueous solubility plays a crucial role in filtering lead compounds and drug candidates in early stages of 
drug discovery and development [1]. Although dependent on the research program, GSK on the basis of 
the General Solubility Equation (GSE, see below) recently suggested that solubility is satisfactory (high) 
when >200 μM, while 30–200 μM was considered as intermediate and <30 μM as poor [2].  
Application of in silico methods is one of the most appealing strategies to overcome solubility issues in 
drug discovery projects [3]. However, predicting solubility is not an easy task mainly because of the high 
uncertainty affecting the experimental data [4], with typical interlaboratory measurement reproducibilities 
of 0.6 log S units (with S in mol/L) [5]. The main approaches for prediction of solubility have recently been 
reviewed by Bergström and Larsson [6] and Abramov et al. [7]. In summary, solubility can be predicted 
using either of two methods: Quantitative Structure Property Relationships (QSPR), which includes the 
GSE, and physics-based methods based on modelling of the thermodynamic cycle. The GSE, physics-based 
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methods and a few QSPRs build on the three key steps taken when a molecule transitions from the 
crystalline state into an aqueous solution [6], i.e. a) dissociation from the crystal lattice [main descriptor: 
the melting point (MP)], b) preparation of a solvent cavity for incorporation of the molecule [main 
descriptor: the molecular weight (MW)] and c) insertion of the molecule in the solvent cavity and 
interactions with water [main descriptor: the logarithm of the partition coefficient between octanol and 
water (log P)]. In general, higher values for each of these three descriptors result in lower solubilities, but 
they are not by themselves providing perfect explanations of the individual steps in the solubilization 
process. For example, cavity formation could be better described by the molecular volume, which in turn is 
closely correlated to molecular weight. It was recently demonstrated that the solid-state contribution is 
the limiting factor in the accuracy and predictive power of models of solubility [8]. Therefore, if the 
solubility of a series of compounds is mainly controlled by their crystal packing, it is difficult to obtain an 
accurate prediction [3]. In such situations the application of a quantum mechanical (QM)-based 
thermodynamic cycle approach has been suggested [7]. However, if the solubility of a compound is mainly 
governed by lipophilicity, it is easier to predict its solubility with good accuracy. 
Drug discovery for difficult-to-drug targets often results in ligands that are large, highly lipophilic and 
semi-flexible compounds, i.e. compounds residing in the “beyond rule of 5” (bRo5) chemical space [9]. 
Development of such compounds is associated with high pharmacokinetic risks, low solubility being one of 
them [10]. In addition to the aforementioned difficulties, additional issues in the prediction of solubility are 
encountered when dealing with bRo5 compounds. First, the low amount of experimental data available in 
the public domain limits the generation of models. Second, many drugs in this space display chameleon-
like behaviour (i.e. they adapt their properties to the environment) which originates from their semi-
flexibility and results in dynamic formation of intra-molecular hydrogen bonds (IMHBs) [11] and/or 
shielding of polar surface area [12,13]. This introduces an additional level of complexity that should be 
taken into account in any modelling procedure. 
To provide an update about the current status of solubility modelling in the bRo5 chemical space we 
first review the few bRo5 solubility models described in the literature. Then we report some computational 
strategies we applied to model the solubility of a dataset of ten bRo5 drugs and drug candidates, and to a 
second larger dataset of natural product inspired macrocycles. Lastly, we have summarized some key 
findings and attempted to set up preliminary guidelines for how to obtain reliable solubility models for 
drug discovery in the bRo5 chemical space. 
Recent developments 
We recently investigated the solubility of a structurally diverse set of 11 drugs residing far into the bRo5 
chemical space [12]. The selected drugs consisted of erythronolides and rifamycin antibacterial agents, as 
well as HIV-1 and HCV NS3/4A protease inhibitors. As determined by X-ray crystallography each drug 
populated >2 different conformations (RMSD >1.4 Å). Due to the difficulties in predicting the relevant 
conformational space for bRo5 drugs [14], these experimentally determined conformations were used to 
assess the impact of using 3D descriptors when modelling solubility. Solubility determined at pH 7.4, where 
seven of the drugs were ionized, was used in the solubility models, i.e. S (solubility at a given pH where the 
molecules can be fully or partially ionized) and not S0 (solubility of the neutral species) was used. We found 
that aqueous solubility was explained to some extent by the 2D descriptor of polarity, i.e. TPSA (r2 = 0.53), 
but that the correlation improved substantially when descriptors calculated from the 3D structures of the 
drugs [15] were used. The best model was based on the conformation of each drug that had the maximum 
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molecular 3D PSA (Max M 3D-PSA, r
2
 = 0.83), while use of solvent accessible 3D PSA provided inferior 
models. The positive slopes of the correlations support, as expected, that the larger the PSA, the more 
soluble the drug. Notably, only a small difference in the quality of the regression model was obtained when 
the minimum molecular 3D-PSA was used instead of the Max M 3D-PSA. This finding, together with the 
observation that use of solvent accessible 3D PSA provided inferior models, suggests that the overall 
polarity of the molecule, originating from sampling of multiple aqueous conformations, is the most 
predictive for solubility. Solubility was also very well modelled by experimental lipophilicity (i.e. log D7.4) 
since the correlation between log S and log D7.4 had r
2
= 0.82. However, the relationship between solubility 
and calculated lipophilicity was not sought. 
Very recently Avdeef and Kansy investigated to what extent the solubilities of small, Ro5-compliant 
molecules can be used to predict the intrinsic aqueous solubility of large molecules in the bRo5 chemical 
space [16]. Three solubility models published for Ro5 compliant molecules [4] were used to predict the 
solubility of a set of 31 bRo5 compounds, for which carefully curated log S0 values have been reported. The 
GSE and the Abraham Solvation Equation failed to predict the solubility of the larger compounds in bRo5 
space, whereas the Random Forest Regression (RFR) method provided better results. The three methods 
differ in the applied algorithm, but also in the number of descriptors. Three were used in the GSE, five or 
six in the Abraham Solvation Equation and about 200 in RFR. Notably, 3D structural information was not 
used, but the authors suggest that the use of 3D descriptors (e.g. lipophilicity) could significantly improve 
predictions, since flexibility and conformational preferences can be expected to be more important for big 
than for small molecules. 
Cyclic peptides are useful model systems for mapping solubility in the bRo5 chemical space, and also of 
major interest as leads on drug discovery projects. Qualitative structure-solubility relationships have been 
reported for cyclic peptides, but to the best of our ability we have not found any specific quantitative 
models. For instance, Lokey and co-workers reported that small variations in the side chains of synthetic 
analogues of the cyclic peptide natural product sanguinamide A had a large effect on their aqueous 
solubility [17]. Interestingly, in depth studies of three of the cyclic peptides revealed that the one that 
displayed conformational flexibility had chameleon-like behaviour resulting in high solubility and cell 
permeability, where two rigid analogues had low solubility but retained the high permeability. Another 
paper from the same group further exemplified the importance of conformational flexibility and 
chameleon-like behaviour for conveying high solubility and permeability of cyclic peptides from the 
phepropeptin and epiphepropeptin series [18]. Overall, these studies suggest that flexibility and 
conformational preferences should be included in the prediction of the solubility of cyclic peptides, but a 
more general approach on how to do this in practice still remains to be described. 
Solubility models for a small set of bRo5 drugs 
We investigated additional methods to model solubility for 10 of the 11 drugs studied earlier by us 
(rifampicin was excluded because of its zwitterionic nature) [12]. As lipophilicity is one of the three major 
determinants of solubility according to the GSE, and as the size of these 10 drugs does not show a large 
variation (MW 671-837 Da), we focused the modelling on log P and log D calculated by different methods 
(Figure 1, all data are in Table S1). MlogP, the 2D lipophilicity descriptor implemented in the Lipinski’s Ro5, 
provided a moderate correlation with log S (Figure 1A). As expected, significantly better correlations were 
obtained with log D7.4 calculated by MoKa (www.moldiscovery.com) and log D7.5 from VolSurf+ (VS+, 
www.moldiscovery.com), highlighting the importance of incorporating the charge of the drug in the 
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models (Figures 1B and 1C). It is worth to note that inclusion of 3D structural information [log D7.5 (VS+)] 
did not significantly improve the statistical significance of the regression model found with 2D log D 
[log D7.4 (MoKa)] for this set of bRo5 drugs. 
 
Figure 1. Solubility models for a dataset of 10 drugs in bRo5 space. Experimentally determined solubility at pH 
7.4 (log S) and its correlation to (a) MlogP, implemented in the Ro5, (b) log D7.4 calculated in MoKa, (c) log D7.5 
calculated using VolSurf+, and (d) log S7.5 calculated using VolSurf+. 
VolSurf+ also allows calculation of log S0 and log S at different pH values. We predicted log S7.5 (VS+) 
based on 3D descriptors derived from an average conformation produced by the software from the SMILES 
code of each of the 10 drugs. However, the correlation between log S7.5 (VS+) and the experimentally 
determined solubility (Figure 1D) was of lower quality than those obtained with log D descriptors (Figures 
1B and 1C).  
Besides VolSurf+ some other in silico tools apply 2D models to the prediction of solubility from SMILES 
codes. Most if not all of them have been set-up using datasets of small molecules having solubility values 
curated at different levels of quality. Nevertheless, considering the free availability and user-friendly 
interfaces we decided to evaluate them in the bRo5 chemical space. The SMILES codes of the 10 drugs 
were therefore submitted to admetSAR (http://lmmd.ecust.edu.cn/admetsar2/), ADMETLab 
(http://admet.scbdd.com/calcpre/index/), pKCSM (http://biosig.unimelb.edu.au/pkcsm) and Marvin 
Sketch (https://chemaxon.com/products/marvin). Notably, only log S calculated with Marvin Sketch 
provided a good linear relationship with the experimental data (r2=0.81 with log S, 0.59 with log S0; all the 
data are in Table S2). However, the slope and the intercept were significantly different from 1 and 0 (0.42 
and -2.61, respectively) and thus the predicted values are not close to the experimental ones. 
A solubility classification model for a set of structurally complex macrocycles 
Previously, some of us determined the aqueous solubility, lipophilicity (log D) and permeability across 
Caco-2 cell monolayers for a set of 200 non-peptidic, de novo–designed macrocycles, the structures of 
which were inspired by natural products [19]. In-depth analysis of this dataset revealed that stereo- and 
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regiochemistry can have a large influence on passive permeability and cellular efflux, whereas their impact 
on solubility appeared to be lower. Moreover, an appropriate conformational flexibility was concluded to 
be a highly desirable property that may provide compounds in bRo5 space with chameleonic properties 
that allow them to display both high aqueous solubility and high cell permeability. However, as structure-
solubility relationships were not investigated for this set of macrocycles we now selected a subset 
consisting of 65 of the macrocycles for more detailed studies. The macrocycles in this set were selected by 
having no or very low efflux across Caco-2 cells (ER <2), i.e. by possessing one important property 
favourable for development of drugs in bRo5 space. The solubility distribution of the subset suggested that 
a classification rather than a regression strategy should be applied (Figure 2), and the threshold to 
distinguish soluble (47) from poorly soluble (18) compounds was fixed at 50 M. This is a slightly more 
liberal cut-off than that proposed by GSK (30 M) to distinguish compounds having poor from those having 






Figure 2. Distribution of the aqueous solubility 
for the de-novo designed macrocycles. 
 
 
In contrast to the 10 bRo5 drugs discussed above, descriptors for lipophilicity (log P or log D) failed to 
provide models for solubility for this set of de novo-designed macrocycles (data not shown) and therefore 
more complex methods were investigated. The CORINA (https://www.mn-am.com/online_demos/-
corina_demo) conformer of the charged and neutral forms of the selected macrocycles was obtained and 
conformational sampling was performed for both forms using OMEGA (https://www.eyesopen.com/-
omega). Then descriptors were calculated for (1) the 2D structure (which provided the 2D dataset), (2) the 
CORINA conformer (named 3D) and (3) the minimum energy conformer from OMEGA (named MEC). A 
pool of 2D descriptors were calculated for the first (2D) dataset, while both 2D and 3D descriptors were 
calculated for the 3D and MEC datasets. Random Forest (RF) classification models were built for data 
matrixes using WEKA v3.8 (https://www.cs.waikato.ac.nz/ml/weka/) and their quality was evaluated using 
the Matthews Correlation Coefficient (MCC), which takes into account true positives and negatives and 
returns a value between -1 and +1. A perfect prediction is characterized by a coefficient of +1, a random 
prediction by 0, while a completely incorrect prediction has an MCC of -1. In general, models having MCC 
values greater than 0.4 are considered to be predictive. 
All models for this set of macrocycles were of good or high quality (Table 1, Leave-5-Out crossvalidation 
was used), but those obtained for the charged species, (MCC: 0.84 – 1.00) were superior to those for the 
neutral species (MCC = 0.43 – 0.92). This finding agrees well with the fact that most macrocycles in the 
dataset are predicted to be positively charged at pH 7.4. Notably, the best model (MCC = 1) was obtained 
for the charged forms using only 2D descriptors, while slightly inferior models were obtained when 3D 
descriptors were incorporated. The classification models were further assessed using an internal test set 
obtained by splitting the dataset into a training (50 macrocycles) and a test set (15 macrocycles). Again, the 
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2D-based RF model performed better than the models that included 3D information from conformational 
sampling (MCC = 0.71, Table S3). Eleven descriptors were found to have a high impact on the RF 
classification models, among which those describing lipophilicity, charge and surface area descriptors are 
the most important (Table S4). 
Table 1. Summary of solubility classification models for the DOS macrocyclic dataset (Five-fold cross 
validation, #descriptors = number of descriptors of the model; TP = true positives, FN = false 
negatives; TN = true negatives; FP = false positives, MCC = Matthews Correlation Coefficient) 






 2D 3 39 8 11 7 0.43 
3D 12 46 1 17 1 0.92 






 2D 11 47 0 18 0 1.00 
3D 5 46 0 18 1 0.96 
MEC 10 46 1 15 3 0.84 
General considerations on solubility in the bRo5 chemical space 
The previous sections clearly support that different bRo5 datasets can require different strategies for 
modelling of their solubility. For instance, the solubility of the 10 drugs in bRo5 space showed an excellent 
correlation with calculated log D only, whereas the solubility of the de-novo designed set of macrocycles 
required development of an advanced RF model. Overall, these observations highlight that models 
developed for specific, small datasets usually cannot be transferred to other datasets. 
Another key observation is that the impact of ionization on solubility cannot be neglected when dealing 
with bRo5 compounds, just as for Ro5 compliant small molecules. Therefore, the pKa of the investigated 
compounds should be accurately predicted before modelling solubility, which is a far from an easy and 
trivial task. Moreover, lipophilicity and polarity descriptors are needed to model solubility, but they should 
be specifically designed and validated for large and flexible compounds. 
In principle, a 3D description of compounds in bRo5 space should be important for modelling solubility 
since conformational changes that expose surfaces with different properties could be required when a 
molecule dissociates from the crystal lattice and moves into solution. However, the examples discussed 
herein seem to suggest that the impact of the 3rd dimension on solubility is less important than for cell 
permeability. In fact, inclusion of 3D descriptors failed to improve the solubility models both for the 10 
bRo5 drugs [12] and for the de-novo designed macrocycles [19]. In contrast, Avdeef and Kansy suggested 
that inclusion of 3D information might be important [16], and this is also observed for the cyclic peptides 
studied by Lokey and co-workers [17,18]. Thus, it remains to be established if modelling of aqueous 
solubility is facilitated by methods for prediction of the conformations adopted in aqueous solution. 
However, we recently showed that reproducing experimental conformations by tools designed for 
conformational sampling of large and macrocyclic compounds is far from being an easy task [14].  
Overall, more experimental data is needed to draw general conclusions about what the best approaches 
are for modelling the solubility of large and flexible compounds. This data is likely to be available in the 
pharmaceutical industry and partnering with academic researchers could be the preferred way to further 
analysis. We hope that this weakness can be overcome so that more reliable methods for prediction of the 
solubility of compounds lying in the bRo5 chemical space can be developed. 
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